News

Depression in type-1 diabetes patients is associated with higher levels of the inflammatory protein galectin-3. These findings suggest that galectin-3 levels may be a new target for treating depression associated with type-1 diabetes, which could lead to better patient care.

Researchers have shown that some tumors use not one but two levels of protection against the immune system. Knocking out one level boosted the protective effects of the second and vice versa. A two-pronged approach targeting both cell types simultaneously may offer a promising route for the development of new cancer immunotherapies.

Astrocytic activation in the hippocampus, a brain region that plays an important role in memory acquisition and consolidation.

A protein in the brain that binds to alcohol could be the key to curing alcoholism

The human glutamine transporter ASCT2 is upregulated in several forms of cancer. It is also the docking platform for a wide range of pathogenic retroviruses. A team of University of Groningen scientists have used cryo-electron microscopy to elucidate the structure of the protein, which may generate leads for drug development.

New technology improves on one that only a decade ago seemed magical.

Fecal microbiota transplant (FMT) is widely regarded as the most effective treatment for a dangerous intestinal infection known as Clostridium difficile (C. diff). Appealing to a concern for others is the best way to recruit most people to donate their stool for medicine, while cash rewards may be an additional motivator for some potential donors, according to new research.

Novel cannabinoid formulation, RAPID, is being tested for the treatment of stress and anxiety relief, cognitive focus, various kinds of pain and, migraines and could help curb opioid use.

International competition rewards four top proteomics researchers for outstanding innovation and impact.

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab. Often, the problem is that while treatments initially work, cancer evolves to resist treatment. Colorado study suggests new combination treatment against relapsed head and neck cancer.